Abstract
Summary: Patients (n=22) with metastatic or unresectable colorectal carcinoma were treated with interleukin (IL)-2 and lymphokine-activated killer (LAK) cells in a phase II study conducted by the IL-2/LAK Working Group (ILWG). Eligilbility criteria for the study included bidimensionally measurable disease, performance status 0 or 1, and normal function of all vital organs. The median age of patients was 49 (range, 28–61)years. Eight (36%) patients had never received prior radiotherapy, and 12 (55%) chemotherapy. No patients had received prior immunotherapy. Treatment consisted of Il-2, 600,000 IU/kg administered lby 15 min intravenous infusion every 8 h on days 1–5 and 12–16. Patients underwent 4-h leukapheresis on days 8–12, and cells were placed in in vitro culture with IL-2 for 3–4 days and the activated LAK cells were infused over 1 h on days 12, 13, and 15. All doses of IL-2 and LAK cells were administered to patients in intensive care unit (ICU) settings. The mean ± SD number of IL-2 doses administered during days 1–5 was 13.4 ± 1.2, the mean number of LAK cells reinfused was 6.8 ± 2.2 x 10<sup>10</sup>, and the mean number of IL-2 doses administered during the last phase was 9.8 ± 2.5. Nineteen patients completed the IL-2 priming phase and received at least one LAK cell infusion. One patient achieved a complete response and was progression free for 8 months from the beginning of treatment for an overall objective response rate of 5% (95% confidence interval: 0–13%). Hyp9otension, weight gain, anemia, and elevations of serum creatinine and liver enzymes were common, but there were no treatment-related death. Treatment delivered and tozicity were comparable to lthose reported in studies conducted concurrently for other malignancies. We conclude that high-dose IL-2 with other immunotherapeutic approache.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 74-78 |
| Number of pages | 5 |
| Journal | Journal of Immunotherapy |
| Volume | 15 |
| Issue number | 1 |
| State | Published - 1994 |
Fingerprint
Keywords
- Colorectal carcinoma
- Interleukin-2
- Lymphokine-activated Killer cells
ASJC Scopus subject areas
- Cancer Research
- Immunology
- Immunology and Allergy
- Pharmacology
Cite this
A Phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. / Hawkins, Michael J.; Atkins, Michael B.; Dutcher, Janice P.; Fisher, Richard I.; Weiss, Geoffrey R.; Margolin, Kim A.; Rayner, Anthony A.; Sznol, Mario; Parkinson, David R.; Paietta, Elisabeth M.; Gaynor, Ellen R.; Boldt, David H.; Doroshow, James H.; Aronson, Frederick R.
In: Journal of Immunotherapy, Vol. 15, No. 1, 1994, p. 74-78.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A Phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma
AU - Hawkins, Michael J.
AU - Atkins, Michael B.
AU - Dutcher, Janice P.
AU - Fisher, Richard I.
AU - Weiss, Geoffrey R.
AU - Margolin, Kim A.
AU - Rayner, Anthony A.
AU - Sznol, Mario
AU - Parkinson, David R.
AU - Paietta, Elisabeth M.
AU - Gaynor, Ellen R.
AU - Boldt, David H.
AU - Doroshow, James H.
AU - Aronson, Frederick R.
PY - 1994
Y1 - 1994
N2 - Summary: Patients (n=22) with metastatic or unresectable colorectal carcinoma were treated with interleukin (IL)-2 and lymphokine-activated killer (LAK) cells in a phase II study conducted by the IL-2/LAK Working Group (ILWG). Eligilbility criteria for the study included bidimensionally measurable disease, performance status 0 or 1, and normal function of all vital organs. The median age of patients was 49 (range, 28–61)years. Eight (36%) patients had never received prior radiotherapy, and 12 (55%) chemotherapy. No patients had received prior immunotherapy. Treatment consisted of Il-2, 600,000 IU/kg administered lby 15 min intravenous infusion every 8 h on days 1–5 and 12–16. Patients underwent 4-h leukapheresis on days 8–12, and cells were placed in in vitro culture with IL-2 for 3–4 days and the activated LAK cells were infused over 1 h on days 12, 13, and 15. All doses of IL-2 and LAK cells were administered to patients in intensive care unit (ICU) settings. The mean ± SD number of IL-2 doses administered during days 1–5 was 13.4 ± 1.2, the mean number of LAK cells reinfused was 6.8 ± 2.2 x 1010, and the mean number of IL-2 doses administered during the last phase was 9.8 ± 2.5. Nineteen patients completed the IL-2 priming phase and received at least one LAK cell infusion. One patient achieved a complete response and was progression free for 8 months from the beginning of treatment for an overall objective response rate of 5% (95% confidence interval: 0–13%). Hyp9otension, weight gain, anemia, and elevations of serum creatinine and liver enzymes were common, but there were no treatment-related death. Treatment delivered and tozicity were comparable to lthose reported in studies conducted concurrently for other malignancies. We conclude that high-dose IL-2 with other immunotherapeutic approache.
AB - Summary: Patients (n=22) with metastatic or unresectable colorectal carcinoma were treated with interleukin (IL)-2 and lymphokine-activated killer (LAK) cells in a phase II study conducted by the IL-2/LAK Working Group (ILWG). Eligilbility criteria for the study included bidimensionally measurable disease, performance status 0 or 1, and normal function of all vital organs. The median age of patients was 49 (range, 28–61)years. Eight (36%) patients had never received prior radiotherapy, and 12 (55%) chemotherapy. No patients had received prior immunotherapy. Treatment consisted of Il-2, 600,000 IU/kg administered lby 15 min intravenous infusion every 8 h on days 1–5 and 12–16. Patients underwent 4-h leukapheresis on days 8–12, and cells were placed in in vitro culture with IL-2 for 3–4 days and the activated LAK cells were infused over 1 h on days 12, 13, and 15. All doses of IL-2 and LAK cells were administered to patients in intensive care unit (ICU) settings. The mean ± SD number of IL-2 doses administered during days 1–5 was 13.4 ± 1.2, the mean number of LAK cells reinfused was 6.8 ± 2.2 x 1010, and the mean number of IL-2 doses administered during the last phase was 9.8 ± 2.5. Nineteen patients completed the IL-2 priming phase and received at least one LAK cell infusion. One patient achieved a complete response and was progression free for 8 months from the beginning of treatment for an overall objective response rate of 5% (95% confidence interval: 0–13%). Hyp9otension, weight gain, anemia, and elevations of serum creatinine and liver enzymes were common, but there were no treatment-related death. Treatment delivered and tozicity were comparable to lthose reported in studies conducted concurrently for other malignancies. We conclude that high-dose IL-2 with other immunotherapeutic approache.
KW - Colorectal carcinoma
KW - Interleukin-2
KW - Lymphokine-activated Killer cells
UR - http://www.scopus.com/inward/record.url?scp=0028082117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028082117&partnerID=8YFLogxK
M3 - Article
VL - 15
SP - 74
EP - 78
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
SN - 1053-8550
IS - 1
ER -